Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.72 |
| ▸ | TERT | O14746 | 15/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237670 | 1.00 | CASP3 (0.72) | CASP3TERTMEN1NPC1ALDH1A1 | |
| SCHEMBL4294197 | 1.00 | CASP3 (0.72) | CASP3TERTMEN1NPC1ALDH1A1 | |
| SCHEMBL15427156 | 0.95 | ALDH1A1 (0.72) | CASP3TERTMEN1NPC1ALDH1A1 | |
| SCHEMBL3382902 | 0.94 | ALDH1A1 (0.70) | CASP3TERTMEN1NPC1ALDH1A1 | |
| SCHEMBL1182441 | 0.90 | ALDH1A1 (0.66) | CASP3TERTMEN1NPC1ALDH1A1 | |
| SCHEMBL4294857 | 0.86 | CASP3 (0.74) | CASP3TERT | |
| SCHEMBL9629661 | 0.86 | CASP3 (0.74) | CASP3TERT | |
| SCHEMBL12857989 | 0.84 | CASP3 (1.00) | CASP3ALDH1A1MAPT | |
| SCHEMBL11633144 | 0.83 | CASP3 (0.75) | CASP3TERTMEN1NPC1ALDH1A1 | |
| SCHEMBL4293006 | 0.83 | CASP3 (0.75) | CASP3TERTMEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316234-A1 | ANTHRAQUINONE -BASED COMPOUND, THE SYNTHESIS PROCESSES AND THE APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-12-13 | — | — | US | disclosed |
| US-20120316234-A1 | ANTHRAQUINONE -BASED COMPOUND, THE SYNTHESIS PROCESSES AND THE APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-12-13 | — | — | US | disclosed |
| EP-0482119-A1 | INTERCALATING AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991000265-A1 | INTERCALATING AGENTS | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 1991-01-10 | — | — | WO | disclosed |
| EP-0191058-B1 | COMPOUNDS HAVING AN IMMUNIZING ACTIVITY | CL PHARMA AKTIENGESELLSCHAFT (AT) | 1989-03-29 | — | — | EP | disclosed |
| US-4794125-A | BIS-ALPHA-HALOACYL-AMINOANTHRAQUINONE; ANTITUMOR, LEUKEMIA TREATMENT | CL PHARMA AG (AT) | 1988-12-27 | — | — | US | disclosed |
| EP-0191058-A1 | COMPOUNDS HAVING AN IMMUNIZING ACTIVITY. | BIBER RUDOLF | 1986-08-20 | — | — | EP | disclosed |
| WO-1986000892-A1 | NEW COMPOUNDS HAVING AN IMMUNIZING ACTIVITY | BIBER RUDOLF | 1986-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316234-A1 | ANTHRAQUINONE -BASED COMPOUND, THE SYNTHESIS PROCESSES AND THE APPLICATION THEREOF | AAAS, QPCT, NQO2 | CASP3 1573/4885TERT 2376/4885MEN1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.